New combo therapy shows promise for tough prostate cancer
NCT ID NCT03344211
First seen Nov 17, 2025 · Last updated Apr 30, 2026 · Updated 18 times
Summary
This study looks at how well the drug enzalutamide works alone or with a radiation drug called radium-223 in men with advanced prostate cancer that has spread to bone. The goal is to see if the combination boosts the immune system and slows cancer growth. About 30 men will take part, and researchers will check bone samples for changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
-
City of Hope
Duarte, California, 91010, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.